<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="365930">
  <stage>Registered</stage>
  <submitdate>7/03/2014</submitdate>
  <approvaldate>21/03/2014</approvaldate>
  <actrnumber>ACTRN12614000305628</actrnumber>
  <trial_identification>
    <studytitle>The effect of Coleus forskohlii extract on the risk factors of metabolic syndrome  </studytitle>
    <scientifictitle>Investigation of appetite suppressant properties associated with Coleus forskohlii in overweight and obese individuals  </scientifictitle>
    <utrn>Nil</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Metabolic syndrome</healthcondition>
    <healthcondition>Obesity  </healthcondition>
    <conditioncode>
      <conditioncode1>Diet and Nutrition</conditioncode1>
      <conditioncode2>Obesity</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Alternative and Complementary Medicine</conditioncode1>
      <conditioncode2>Herbal remedies</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Ingestion of 250mg Coleus forskohlii extract twice a day for 12 weeks. Adherence to intervention protocols will be monitored through fortnight consulatation - capsule calendar and food diary will be collected, anthropomentric measurement will be taken in the clinic.</interventions>
    <comparator>Ingestion of 250mg maltodextrin (placebo) twice a day for 12 weeks. Adherence to intervention protocols will be monitored through fortnight consulatation - capsule calendar and food diary will be collected, anthropomentric measurement will be taken in the clinic.</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>changes in appetite will be assessed using visual analogue scale; blood hormone levels will also be measured using commercial kits.  </outcome>
      <timepoint>12 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>reduction in central obesity - waist circumference will be measured on fortnight basis.</outcome>
      <timepoint>12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>alterations in blood lipids. This will be measured using commercial kits.</outcome>
      <timepoint>12 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Overweight or obese (BMI &gt;25), waist circumference of &gt; 94 cm (male), waist circumference of &gt;80 cm (female)</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Cigarette smoker, hypertension, all types of heart, liver and kidney disease, pregnancy, lactating, Type 1 diabetes and weight loss medication.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation is not concealed</concealment>
    <sequence>Stratified allocation will be employed using computer software. Dynamic (adaptive) random allocation methods such as Minimisation will be used. Factors used for the stratification include age, gender, BMI, waist circumference, body weight and height. </sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Randomised, placebo controlled</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>The sample size was determined by statistical power analysis (two tailed t-test at the 5% significance level for the power of 90%) of expected differences in the major measured variables which include total energy intake, fat intake and anthropometry.
ANOVA and t-test using SPSS or Excel software will be performed to analyse the data.</statisticalmethods>
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>False</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/04/2014</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate>31/08/2014</anticipatedenddate>
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Victoria University</primarysponsorname>
    <primarysponsoraddress>McKechnie Street 
St Albans
PO Box 14428
Melbourne 
VIC, 8001</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Victoria University</fundingname>
      <fundingaddress>McKechnie Street 
St Albans
PO Box 14428
Melbourne 
VIC 8001</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Olive Life Science</sponsorname>
      <sponsoraddress>No 30, Pride Quadra, 4th floor
Hebbal, Bangalore 560024
Karnataka</sponsoraddress>
      <sponsorcountry>India</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Coleus forskohlii extract contains the bioactive compound, forskolin. Preliminary studies have shown that forskolin can increase fat metabolism thus reduce fat accumulation in both animals and humans. It has been suggested that forskolin may also suppress appetite thus reduce energy intake and results in weight loss. This study will evaluate the appetite suppressent properties of Coleus forskohlii  extract. In addition the effect on central obesity and risk factors of metabolic syndrome will also be investigated. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Victoria University Ethics Committee</ethicname>
      <ethicaddress>Victoria University
Office for Research
Footscray Park Campus
Ballarat Road, Footscray 
Victoria 3011
</ethicaddress>
      <ethicapprovaldate>3/03/2014</ethicapprovaldate>
      <hrec>HRE14-020</hrec>
      <ethicsubmitdate>29/01/2014</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Xiao Su</name>
      <address>College of Health and Biomedicine
Victoria University
St Albans
PO Box 14428
Melbourne 
VIC 8001</address>
      <phone>+61 3 99192318</phone>
      <fax>+61 3 99192465</fax>
      <email>Xiao.Su@vu.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Miss</title>
      <name>Hayley Loftus</name>
      <address>College of Health and Biomedicine
Victoria University
St Albans
PO Box 14428
Melbourne 
VIC 8001</address>
      <phone>+61 431580501 </phone>
      <fax>+61 3 99192465</fax>
      <email>hayley.loftus@live.vu.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Michael Mathai</name>
      <address>College of Health and Biomedicine
Victoria University
St Albans
PO Box 14428
Melbourne 
VIC 8001</address>
      <phone>+61 3 99192211</phone>
      <fax>+61 3 99192465</fax>
      <email>Michael.Mathai@vu.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Xiao Su</name>
      <address>College of Health and Biomedicine
Victoria University
St Albans
PO Box 14428
Melbourne 
VIC 9001</address>
      <phone>+61 3 99192318</phone>
      <fax>+61 3 99192465</fax>
      <email>Xiao.Su@vu.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>